These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 1985692)

  • 1. Response rates and survival in primary systemic amyloidosis.
    Gertz MA; Kyle RA; Greipp PR
    Blood; 1991 Jan; 77(2):257-62. PubMed ID: 1985692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: one-year follow-up in five patients.
    Comenzo RL; Vosburgh E; Simms RW; Bergethon P; Sarnacki D; Finn K; Dubrey S; Faller DV; Wright DG; Falk RH; Skinner M
    Blood; 1996 Oct; 88(7):2801-6. PubMed ID: 8839879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary systemic amyloidosis: resolution of the nephrotic syndrome with melphalan and prednisone.
    Kyle RA; Wagoner RD; Holley KE
    Arch Intern Med; 1982 Aug; 142(8):1445-7. PubMed ID: 7103624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of AL amyloidosis with melphalan, prednisone, and colchicine.
    Benson MD
    Arthritis Rheum; 1986 May; 29(5):683-7. PubMed ID: 3718560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary systemic amyloidosis with delayed progression to multiple myeloma.
    Rajkumar SV; Gertz MA; Kyle RA
    Cancer; 1998 Apr; 82(8):1501-5. PubMed ID: 9554527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resolution of primary amyloidosis during chemotherapy. Studies in a patient with nephrotic syndrome.
    Cohen HJ; Lessin LS; Hallal J; Burkholder P
    Ann Intern Med; 1975 Apr; 82(4):466-73. PubMed ID: 1119764
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapy of primary amyloidosis with melphalan and prednisone.
    Schwartz RS; Cohen JR; Schrier SL
    Arch Intern Med; 1979 Oct; 139(10):1144-7. PubMed ID: 485747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective randomized trial of melphalan and prednisone versus vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of primary systemic amyloidosis.
    Gertz MA; Lacy MQ; Lust JA; Greipp PR; Witzig TE; Kyle RA
    J Clin Oncol; 1999 Jan; 17(1):262-7. PubMed ID: 10458241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term survival (10 years or more) in 30 patients with primary amyloidosis.
    Kyle RA; Gertz MA; Greipp PR; Witzig TE; Lust JA; Lacy MQ; Therneau TM
    Blood; 1999 Feb; 93(3):1062-6. PubMed ID: 9920856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute leukemia and cytogenetic abnormalities complicating melphalan treatment of primary systemic amyloidosis.
    Gertz MA; Kyle RA
    Arch Intern Med; 1990 Mar; 150(3):629-33. PubMed ID: 2310282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine.
    Kyle RA; Gertz MA; Greipp PR; Witzig TE; Lust JA; Lacy MQ; Therneau TM
    N Engl J Med; 1997 Apr; 336(17):1202-7. PubMed ID: 9110907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-dose continuous oral melphalan for the treatment of primary systemic (AL) amyloidosis.
    Sanchorawala V; Wright DG; Seldin DC; Falk RH; Berk JL; Dember LM; Finn KT; Skinner M
    Br J Haematol; 2002 Jun; 117(4):886-9. PubMed ID: 12060126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients.
    Comenzo RL; Vosburgh E; Falk RH; Sanchorawala V; Reisinger J; Dubrey S; Dember LM; Berk JL; Akpek G; LaValley M; O'hara C; Arkin CF; Wright DG; Skinner M
    Blood; 1998 May; 91(10):3662-70. PubMed ID: 9573002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary systemic amyloidosis: comparison of melphalan and prednisone versus placebo.
    Kyle RA; Greipp PR
    Blood; 1978 Oct; 52(4):818-27. PubMed ID: 356916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only.
    Skinner M; Anderson J; Simms R; Falk R; Wang M; Libbey C; Jones LA; Cohen AS
    Am J Med; 1996 Mar; 100(3):290-8. PubMed ID: 8629674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis.
    Sanchorawala V; Wright DG; Seldin DC; Dember LM; Finn K; Falk RH; Berk J; Quillen K; Skinner M
    Bone Marrow Transplant; 2001 Oct; 28(7):637-42. PubMed ID: 11704785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Primary amyloidosis associated to severe factor X deficiency].
    Pérez Martínez J; Llamas F; López Montes A; Massó P; Poblet E; López Rubio E; Gallego E; Gómez Roldán C
    Nefrologia; 2004; 24(5):493-8. PubMed ID: 15648909
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Therapy options in systemic AL-amyloidosis with renal involvement].
    Hetzel GR; Schneider P; Mondry A; Heering P; Heyll A; Grabensee B
    Dtsch Med Wochenschr; 2000 Aug; 125(34-35):997-1002. PubMed ID: 11004911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary systemic amyloidosis.
    Comenzo RL
    Curr Treat Options Oncol; 2000 Apr; 1(1):83-9. PubMed ID: 12057064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of recombinant interferon alfa-2 in the treatment of primary systemic amyloidosis.
    Gertz MA; Kyle RA
    Am J Hematol; 1993 Oct; 44(2):125-8. PubMed ID: 8266917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.